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Frozen shoulder is a common fibroproliferative disease character-
ized by the insidious onset of pain and restricted range of shoulder
movement with a significant socioeconomic impact. The patho-
physiological mechanisms responsible for chronic inflammation
and matrix remodeling in this prevalent fibrotic disorder remain
unclear; however, increasing evidence implicates dysregulated
immunobiology. IL-17A is a key cytokine associated with inflam-
mation and tissue remodeling in numerous musculoskeletal dis-
eases, and thus, we sought to determine the role of IL-17A in
the immunopathogenesis of frozen shoulder. We demonstrate
an immune cell landscape that switches from a predominantly
macrophage population in nondiseased tissue to a T cell–rich en-
vironment in disease. Furthermore, we observed a subpopulation
of IL-17A–producing T cells capable of inducing profibrotic and
inflammatory responses in diseased fibroblasts through enhanced
expression of the signaling receptor IL-17RA, rendering diseased
cells more sensitive to IL-17A. We further established that the ef-
fects of IL-17A on diseased fibroblasts was TRAF-6/NF-κB depen-
dent and could be inhibited by treatment with an IKKβ inhibitor or
anti–IL-17A antibody. Accordingly, targeting of the IL-17A path-
way may provide future therapeutic approaches to the manage-
ment of this common, debilitating disease.
frozen shoulder | T cell | IL-17A | inflammation | adhesive capsulitis
Frozen shoulder, also known as adhesive capsulitis, is a verycommon painful condition of the shoulder that can affect up
10% of people of working age (1). Clinically, it manifests as pro-
gressively limited joint movement in all directions associated with
pain and loss of function (2). Frozen shoulder is more prevalent in
women, mainly affecting those in the fifth and sixth decades of life,
and is the third most common cause of musculoskeletal disability in
the United States and European Union (3). While often thought of
as a self-limiting disease, the majority of patients suffer permanent
disability at long-term follow up, with some patients reporting
painful symptoms at 6-y postdisease onset (4), costing the US
healthcare system in excess of $85 million per annum (5). Nu-
merous rehabilitative, medical, and surgical therapies are available
(2); however, current research does not support a clear treatment
strategy, and none are derived from an understanding of the mo-
lecular mechanisms underpinning disease pathology.
The principal structure affected in this disease is the shoulder
capsule, with pathological changes culminating in tissue fibrosis.
Inflammation is known to play a crucial role in tissue fibrosis,
and various proinflammatory cytokines have been implicated in
driving the progression of many fibrotic diseases (6–8). Frozen
shoulder capsular tissue has demonstrated inflammatory cell influx
(9), dysregulated expression of alarmins (HMGB-1, Tenascin C,
IL-33, S100A8, S100A9) (10, 11), inflammatory proteins (IL-1α,
IL-1β, IL-6, TGF-β, COX-1, COX-2, TNF-α) (12, 13), matrix
regulating (matrix metalloproteinases [MMPs] and tissue inhibi-
tors of metalloproteinases [TIMPs]) (12, 14), and markers of
stromal fibroblast activation (PDPN, VCAM, MCAM) (15, 16).
Thus, the presence of immune cells, dysregulated inflammatory/
matrix interactions, and activated fibroblasts allude to a significant
and targetable immune component in the pathogenesis of
frozen shoulder.
IL-17A is a cytokine known to mediate inflammation (17),
fibrosis (18), and pain signaling (19). It is the founding member
of the IL-17 cytokine family and the signature cytokine of the
Th17 T-helper cell population, although it is also expressed by γδ
T cells, innate lymphoid, and natural killer cells (20, 21) The IL-17
receptor family contains five members (A through E), and IL-17A
binds and exerts its downstream effects through an IL-17RA/RC
complex (21). Fibroblasts are among the most responsive cells to
IL-17A and, following IL-17RA/RC binding, induce mitogen-
activated protein kinases, nuclear factor kappa-b (NF-κB), phos-
phoinositide 3 kinase (PI3K), and C/EBP signaling pathways. The
resultant IL-17 “signature” includes, but is not limited to, the
promotion of proinflammatory cytokine, chemokine, and matrix
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metalloproteinase expression from multiple target cells, including
stromal fibroblasts (17, 18, 22–26). IL-17A signaling has been
identified and successfully targeted as a clinical therapy in a host
of chronic inflammatory conditions including ankylosing spondy-
litis and psoriatic arthritis (27–29). Furthermore, we have recently
shown the translational potential of IL-17A in the soft tissue
musculoskeletal condition, tendinopathy (26, 30).
Frozen shoulder has a cellular and molecular profile that is in-
triguingly similar to the manifestation of IL-17A signaling. Based on
these observations, we hypothesized that IL-17A signaling may be
involved in mediating the inflammatory and tissue remodeling
changes present in frozen shoulder in a similar manner to that
which is involved in tendinopathy (26). The purpose of this study
was, firstly, to characterize the immune cell and expression of IL-
17A in human frozen shoulder capsule tissue compared to healthy
control capsule and, secondly, to interrogate IL-17A signaling in
frozen shoulder fibroblasts in vitro to ultimately determine if any
pathogenic effects could be impeded. Herein, we report T cell–
driven IL-17A production and signaling, which induces the fibrotic
features of frozen shoulder. Importantly, we demonstrate that ma-
nipulation of cytokine (IL-17A) signaling and response pathways
can be a therapeutic opportunity for this debilitating disease.
Results
IL-17A–Secreting T Cells in Frozen Shoulder. In order to dissect the
role of immune cells in the fibrotic chronicity of frozen shoulder,
we initially analyzed the immune cells (CD45+) in the shoulder
capsule from control and frozen shoulder tissue. Flow cytometry
of disaggregated tissue demonstrated increased percentage of
CD45+ immune cells in frozen shoulder tissue (Fig. 1A). Further
phenotypic analysis by both flow cytometry and single-cell RNA
sequencing showed that while control capsule immune cells were
predominantly composed of myeloid cells, diseased tissue from
frozen shoulder was mainly comprised of lymphoid cells, primarily
T cells (Fig. 1 A and B and SI Appendix, Fig. S3A). The myeloid
component of immune cells in shoulder capsule tissue can be split
into five subpopulations consisting of macrophages, three pop-
ulations of CD1c dendritic cells (DCs): CD52-expressing DCs, IL-
1 receptor high DCs, and an inflammatory-type DC population
that express cytokines and chemokines such as IL-1β and CXCL8
and CLEC9A DCs (SI Appendix, Fig. S3B). The myeloid cells
found in control capsule tissue are predominantly macrophages
that express LYVE1 and FOLR2. However, the myeloid compo-
nent of immune cells from frozen shoulder tissue contained a
greater proportion of DCs, principally CD52 DCs but with a
considerable proportion of CLEC9A and inflammatory DCs that
are extremely rare in control tissue (SI Appendix, Fig. S3B). The
shift in the myeloid compartment of the shoulder capsule from
primarily macrophages in control tissue to DCs in diseased tissue is
indicative of a T cell response (31). Further analysis of the T cell
constituent from single-cell RNA sequencing data indicated the
presence of eight subpopulations of T cells (Fig. 1C and SI Ap-
pendix, Fig. S4A). Distinct analysis of the T cell populations present
in control tissue demonstrated the primary population to be T cells
with an inactive phenotype (32); interestingly, the proportion of
this population was reduced in the T cell population present in
frozen shoulder tissue (Fig. 1C and SI Appendix, Fig. S4A). This
was also the case with NEAT1-expressing T cells, which were also
less abundant in frozen shoulder tissue compared to control tissue
(Fig. 1C and SI Appendix, Fig. S4A). There was a greater per-
centage of the other six subpopulations of T cells in disease tissue
compared to control tissue (Fig. 1C and SI Appendix, Fig. S4A). Of
particular note was a CD161 CCR6 population which was ex-
panded in frozen shoulder tissue (Fig.1C). This population of cells
was positive for KLRB1(CD161), CCR6, and RORA and negative
for CXCR3 (Fig. 1C and SI Appendix, Fig. S4). This combination of
genes has previously been indicative of IL-17A–producing T cells
(33, 34). As IL-17A has been shown to be pathogenic in numerous
inflammatory diseases (35, 36) as well as a number of fibrotic
pathologies (18, 24, 37), we sought to identify whether IL-17A was
present in diseased shoulder capsule. Gene expression data dem-
onstrated significantly greater expression of IL-17A in frozen
shoulder tissue compared to control (Fig. 1D). Furthermore, im-
munohistochemistry showed the increased presence of IL-
17A–positive cells in frozen shoulder tissue around areas of high
cellularity (Fig. 1D). We subsequently sought to stimulate cells
released from disaggregated frozen shoulder tissue ex vivo to
identify IL-17A–producing T cells. We found that both CD4+ and
CD8+ T cells from frozen shoulder tissue were able to produce IL-
17A following stimulation and intracellular staining (Fig. 1E).
Together, these data highlight the increased presence of T cells in
a chronic fibrotic disorder and their ability to produce IL-17A.
IL-17A Is Profibrotic in Frozen Shoulder. Following confirmation of
the increased presence of IL-17A in frozen shoulder, we sought
to interrogate the role of IL-17A on the fibrotic features of frozen
shoulder in vitro. We were able to demonstrate that IL-17A signifi-
cantly increased the cell viability of frozen shoulder fibroblasts fol-
lowing IL-17A exposure (Fig. 2A). There was also a significant increase
in expression of the antiapoptotic gene BCL2 (38) upon IL-17A ex-
posure (Fig. 2A). Additionally, there was also a significant increase in
cytochrome C measured in the mitochondria of IL-17A–stimulated
frozen shoulder fibroblasts; this was accompanied by a significant de-
crease in the cytochrome C recorded in the cytosol (Fig. 2A). No
significant change in cell viability, BCL2 expression, and mitochondrial
or cytosolic cytochrome C was observed in IL-17A–treated control
fibroblasts compared to untreated fibroblasts, nor was any significant
change detected in cell proliferation and gene expression of proa-
poptotic (38)BAX or cell cycle kinase componentCCND1 (39) in both
control and diseased fibroblasts following IL-17A (Fig. 2A and SI
Appendix, Fig. S6A). These data suggest IL-17A promotes accumula-
tion of fibroblasts in frozen shoulder capsule as a result of up-
regulation of BCL2, which inhibits the release of cytochrome C
from the mitochondria into the cytosol and subsequently suppresses
apoptosis (40, 41) rather than an increase in fibroblast proliferation.
We further explored the fibrotic effects of IL-17A by mea-
suring the gene expression of a number of proteins associated
with fibrotic pathology in frozen shoulder (10, 42, 43). IL-17A
induced no significant changed in the expression of COL1A1,
TNC, or α-SMA in either control or diseased fibroblasts (SI Ap-
pendix, Fig. S6B). However, we did detect significant increase of
COL3A1, FN1, MMP1, and MMP3 gene expression in frozen
shoulder fibroblasts following IL-17A exposure (Fig. 2B). In ad-
dition, we measured significantly greater concentrations of MMP3
in the supernatant of IL-17A–treated frozen shoulder fibroblasts
(Fig. 2B). No significant increase was observed in the expression of
matrix genes or MMP3 in supernatant in control fibroblasts fol-
lowing IL-17A treatment (Fig. 2B), indicating the aberrant tissue
remodeling effects of IL-17A are selective for diseased cells.
IL-17A–Induced Inflammation in Frozen Shoulder. IL-17A is impli-
cated in the pathogenesis of numerous inflammatory diseases
(35, 36). Additionally, frozen shoulder has long been recognized
as having an inflammatory element. Thus, we investigated the pos-
sibility of whether IL-17A could initiate an inflammatory response in
frozen shoulder fibroblasts. Following IL-17A treatment of fibro-
blasts, we assessed the gene expression and protein release of a
number of inflammatory mediators. The data demonstrated that IL-
17A induced an up-regulation of gene expression and release of IL-6
and IL-8 in frozen shoulder fibroblasts (Fig. 2C and SI Appendix, Fig.
S6C). Additionally, the increase in expression of these inflammatory
proteins was significantly greater in diseased fibroblasts compared to
control fibroblasts (Fig. 2C and SI Appendix, Fig. S6C). We also
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Fig. 1. T cells produce IL-17A in frozen shoulder. (A) Percentage and subsets of immune cells phenotyped from disaggregated shoulder capsule tissue. Results
are mean ± SD, n = 4 control capsule and n = 5 frozen shoulder. Statistical analysis using unpaired Student’s t test. * indicates significant difference from
control capsule tissue, *P < 0.05. (B) Uniform Manifold Approximation and Projection (UMAP) embedding of single-cell RNA sequencing and distribution of
immune cells from all shoulder capsule tissue (n = 7, k = 3,347) and split into shoulder capsule of control (n = 3, k = 555 and frozen shoulder tissue (n = 4, k =
2,792). (C) UMAP embedding and distribution of eight delineated T cell populations (CD161 CCR6 T cells, inactive T cells, CD4 T cells, CD8 T cells, natural killer
[NK] cells, NEAT1 T Cells, γδ T cells) in all shoulder capsule tissue (n = 7, k = 1,562) and split into shoulder capsule of control (n = 3, k = 120) and frozen shoulder
tissue (n = 4, k = 1,442). (D) IL-17A gene and protein expression in shoulder capsule tissue. IL-17A expression in control and frozen shoulder capsule, 2-ΔCT
relative to GAPDH, mean ± SD, n = 5 control capsule and n = 10 frozen shoulder. Statistical analysis using unpaired Student’s t test, * indicates significant
difference from control capsule tissue, *P < 0.05. Shoulder capsule tissue stained for IL-17A, isotype IgG in bottom left corner, using rabbit polyclonal IL-17A
antibody at 10× and 40× magnification. Graph illustrates percentage of cells stained positive for IL-17A, mean ± SEM, n = 10 for control, n = 10 for frozen
shoulder tissue. Statistical analysis using unpaired Student’s t test, ****P < 0.0001. (E) IL-17A is produced by T cells from disaggregated frozen shoulder tissue.
Representative flow cytometric plots of unstimulated and stimulated CD3+ T cells following intracellular staining with antibodies against IFN-γ and IL-17A.
Graph displays the proportion of CD4+ and CD8+ T cells positive for IFN-γ and IL-17A (n = 4).
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Fig. 2. IL-17A induces fibrosis and inflammation in vitro. (A) Effect of recombinant IL-17A on control and frozen shoulder fibroblasts viability, BCL2 gene
expression, and mitochondrial and cytosolic cytochrome C content, mean ± SD, n = 4 control fibroblasts and n = 5 frozen shoulder fibroblasts, * indicates
significant difference from untreated cells, *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001, # indicates significant difference from control fibroblasts, #P <
0.05, ##P < 0.01. (B) Effect of IL-17A on COL3A1, FN1, MMP1, MMP3 gene expression and MMP3 protein secretion. mRNA gene expression expressed as fold
change following normalization to housekeeping gene (GAPDH) and then to relevant untreated cells, n = 4 control fibroblasts and n = 5 frozen shoulder
fibroblasts, * indicates significant difference from untreated cells *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001, # indicates significant difference from
control fibroblasts, #P < 0.05, ##P < 0.01 ###P < 0.001. (C) Effect of IL-17A on IL-6, IL-8, CCL20 production from control or frozen shoulder fibroblasts, n = 4
control fibroblasts and n = 5 frozen shoulder fibroblasts, * indicates significant difference from untreated cells *P < 0.05, **P < 0.01, ***P < 0.001, ****P <
0.0001, # indicates significant difference from control fibroblasts, #P < 0.05, ##P < 0.01 ###P < 0.001. All statistical analyses use two-way ANOVA with Dunnet’s
correction or Sidak’s test for multiple comparisons.
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assessed the gene expression of chemokines associated with T cell
recruitment (44–46). There was a significant increase in gene ex-
pression of CCL2, CCL5, and CCL20 in frozen shoulder fibroblasts;
however, no significant increase in the expression of these chemo-
kines was observed in control fibroblasts following IL-17A exposure
(Fig. 2C and SI Appendix, Fig. S6C). We also measured the release
of CCL20 into the supernatant following IL-17A exposure, as it has
previously been shown to be a key recruiter of IL-17A–producing
T cells (45). The concentration of CCL20 from supernatant mir-
rored its gene expression (Fig. 2C and SI Appendix, Fig. S6C) in
which a significant increase was measured in the supernatants of
diseased fibroblasts exposed to 100 ng/mL; however, no significant
increase was measured in the CCL20 release of control fibroblasts
exposed to IL-17A. Together, these data indicate diseased fibro-
blasts from frozen shoulder tissue have greater sensitivity to IL-17A,
thereby inducing a greater response upon stimulation in vitro and
potentially act to further recruit IL-17A–producing T cells.
Enhanced IL-17A Signaling in Frozen Shoulder Is NF-κB Dependent.As
IL-17A was found to influence cell survival and matrix and in-
flammatory proteins in frozen shoulder fibroblasts but not control
fibroblasts, we assessed the role of its receptors and associated
signaling pathways. Gene expression analysis showed that IL-17RA
was the predominant isoform expressed in both control and dis-
eased fibroblasts; however, no significant difference in gene
expression of either IL-17 receptor was observed between control
and frozen shoulder fibroblasts, nor was there any difference in the
protein expression of IL-17RC (SI Appendix, Fig. S5 B and C).
However, Fig. 3 demonstrates that diseased fibroblasts show
greater protein expression of IL-17RA and its downstream effector
TRAF6, supporting the increased sensitivity of diseased cells to IL-
17A stimulation compared to control fibroblasts observed in Fig. 2.
As the TRAF6-dependent pathway in IL-17A signaling is NF-
κB dependent (47, 48), we sought to elucidate whether IL-17A
signaling in frozen shoulder was indeed NF-κB dependent and
whether the profibrotic and inflammatory response could be
blocked by utilizing a small molecule inhibitor we have previously
shown to be effective in a model of tendon disease (49). The
pretreatment of frozen shoulder fibroblasts with 50 nM IKKβ
inhibitor, prior to cytokine exposure, was able to significantly ne-
gate the effects of IL-17A on fibroblast viability and the associated
changes in cytochrome C and BCL2 messenger RNA (mRNA)
expression compared to cells pretreated with a vehicle control
(Fig. 4 A and B). Furthermore, this small molecule inhibitor was
also able to prevent the IL-17A–induced effects on matrix and
inflammatory proteins (Fig. 4 C–E). Hence, the effects of IL-17A
on frozen shoulder fibroblast appear to be mediated via NF-κB.
Translatable Anti–IL-17A Therapy in Fibrosis. The use of an anti–IL-
17A monoclonal antibody has been successful in the treatment of
Fig. 3. Enhanced IL-17RA expression in frozen shoulder fibroblasts. IL-17RA and TRAF6 protein expression in cultured fibroblasts from control and frozen
shoulder capsule. Image of Western blot of protein from control and frozen shoulder fibroblasts immunoblotted for GAPDH, TRAF6, and IL-17RA. Graph
illustrates TRAF6 and IL-17RA protein quantification relative to housekeeping (GAPDH), mean ± SD, n = 4 control and frozen shoulder fibroblasts. Statistical
analysis using Mann–Whitney U rank-sum test. * indicates significant difference from control capsule tissue, *P < 0.05.
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a number of IL-17A–driven inflammatory pathologies (28, 29).
Given our data demonstrated a clear role for IL-17A in driving
disease, we explored the ability of this readily available thera-
peutic agent to inhibit the profibrotic and inflammatory effects in
frozen shoulder. Firstly, we assessed whether this monoclonal
antibody could inhibit IL-17A–induced effects on fibroblast vi-
ability, BCL2 expression, and cytochrome C content. We ob-
served that frozen shoulder fibroblast viability was significantly
lower following pretreatment with the anti–IL-17A antibody prior
to IL-17A exposure compared to cells that were pretreated with
IgG control (Fig. 5A). Additionally, the data demonstrated BCL2
expression and mitochondrial cytochrome C content in cytokine-
stimulated fibroblasts was significantly lower following anti–IL-17A
pretreatment (Fig. 5A). Additionally, the cytosolic cytochrome C
measured in anti–IL-17A–pretreated cells was significantly greater
than that measured in IgG-pretreated cells (Fig. 5A). Furthermore,
we ascertained that anti–IL-17A antibody treatment could suc-
cessfully inhibit the changes in matrix and inflammatory proteins
following IL-17A stimulation in diseased fibroblasts. The data in-
dicate the anti–IL-17A monoclonal antibody could significantly
inhibit the IL-17A–stimulated increase in matrix and inflammatory
gene expression observed in frozen shoulder fibroblasts (Fig. 5B).
Fig. 4. IL-17A signaling is NF-κB dependent in frozen shoulder fibroblasts. (A) Schematic diagram of NF-κB pathway following IL-17A stimulation. Frozen shoulder
fibroblasts were pretreated with IKKβ inhibitor before exposure to IL-17A (100 ng/mL) (B) Fibroblast’s viability, BCL2 gene expression, and mitochondrial and cy-
tosolic cytochrome C content. (C) Gene expression of matrix and inflammatory regulators. mRNA gene expression expressed as fold change following normalization
to housekeeping gene (GAPDH) and then to untreated cells (dashed line). (D) Effect on MMP3 production. (E) Effect on IL-6, IL-8, and CCL20 production. All results
are mean ± SD, n = 4 control and frozen shoulder fibroblasts, * indicates significant difference from untreated cells, *P < 0.05, **P < 0.01, ***P < 0.001. #P < 0.05,
##P < 0.01, ###P < 0.001. All statistical analyses use ANOVA with Bonferroni or Dunn’s correction for multiple comparisons depending on normality.
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In addition, we were able to show that the blockade of IL-17A
signaling via anti–IL-17A treatment was able to significantly inhibit
increased MMP3, IL-6, IL-8, and CCL20 secretion from frozen
shoulder fibroblasts following IL-17A exposure (Fig. 5 C and D).
Together, these data suggest IL-17A signaling inhibition may be a
viable intervention of the fibrotic and inflammatory features ob-
served in frozen shoulder.
Discussion
Our data show the presence of IL-17A–producing T cells in
frozen shoulder capable of inducing profibrotic and inflammatory
effects in diseased fibroblasts through enhanced expression of
the signaling receptor IL-17RA driven by a TRAF6/NF-κB–
dependent pathway. Furthermore, inhibition of IL-17A signaling
via IKKβ inhibition or anti–IL-17A antibodies was able to attenuate
these changes seen in diseased cells. Thus, this study demon-
strates that targeting cytokine-driven immune-mediated pathways
in the common fibrotic condition frozen shoulder is a potential
translational therapy.
Frozen shoulder has historically been described as the inflam-
matory fibrosis of the shoulder capsule, resulting in debilitat-
ing pain and loss of movement (13, 50). Previous investigations
Fig. 5. Anti–IL-17A monoclonal targeting of IL-17A induced fibrotic and inflammatory effects in frozen shoulder. Frozen shoulder fibroblasts were pretreated with
an anti–IL-17A monoclonal antibody or IgG control before exposure to IL-17A (100 ng/mL). (A) Fibroblast’s viability, BCL2 gene expression, and mitochondrial and
cytosolic cytochrome C content. (B) Gene expression of matrix and inflammatory regulators. mRNA gene expression expressed as fold change following normali-
zation to housekeeping gene (GAPDH) and then to untreated cells (dashed line). (C) Effect on MMP3 production. (D) Effect on IL-6, IL-8 and CCL20 production. All
results are mean ± SD, n = 4 control and frozen shoulder fibroblasts, * indicates significant difference from untreated cells, *P < 0.05, **P < 0.01, ****P < 0.001, #P <
0.05, ##P < 0.01, ####P < 0.0001. All statistical analyses use ANOVA with Bonferroni or Dunn’s correction for multiple comparisons depending on normality.
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identified the infiltration of immune cells within the capsule in
biopsies taken from patients undergoing surgery for frozen shoul-
der, confirming the presence of B cells, macrophages, mast cells,
and T cells (9). Although other studies have also demonstrated
positive macrophage staining in similar tissue biopsies (16, 51),
neither have directly compared them to immune cells in the non-
diseased shoulder capsule. The current study demonstrates the shift
from the predominance of macrophages to DCs and T cells in the
immune cell compartment within the shoulder capsule following
the onset of disease. The presence of multiple DC and T cell
populations in diseased capsule tissue highlights a potential critical
role for these cells in the pathogenesis of frozen shoulder. While we
have focused mainly on IL-17A–producing T cells, it is likely to be
the case that immune cell–driven fibrosis is multidimensional, with
critical roles for a number of these cell subpopulations; this should
be explored further to elucidate the pathogenesis of fibrotic dis-
orders and possible subsequent therapeutic targeting. Interestingly,
the main macrophage population we found in control capsule is
phenotypically similar (LYVE1 and MERTK expressing [SI Ap-
pendix, Fig. S3B]) to those found in rheumatoid arthritis patients
under remission that were shown to be negative regulators of in-
flammation and induced repair responses in synovial fibroblasts
in vitro (52). We postulate this reduced presence of resolutory
macrophages may indicate a loss of regulation or aberrant tissue
repair, resulting in the myeloid component becoming dominated by
multiple DC populations and subsequent influx of pathogenic
T cells.
The presence of T cells within fibrotic pathologies is well
established; in particular, IL-4– and IL-13–secreting T cells are
known to induce fibrosis (6–8). However, recently there has been
accumulating data demonstrating the role of IFN-γ– (53) or IL-
17A– (24, 37, 54) secreting T cells in the pathogenesis of fibrotic
disorders (17, 18) as well as determining pathways of repair
following tissue damage (55). Similar to these data, we demon-
strate that IL-17A can directly promote a number of profibrotic
mechanisms, including fibroblast survival and enhanced gene
expression of proteins associated with matrix deposition. These
profibrotic characteristics have previously been attributed to the
elevated levels of the cytokine TGF-β in frozen shoulder (12, 14,
56). However, our data suggest the presence of IL-17A can also
encourage the fibrotic hallmarks of frozen shoulder.
The inflammatory effect effects of IL-17A on fibroblasts are
well established (17, 25, 37, 47). We were able to support these
previous findings by demonstrating increased expression of a number
of cytokines and chemokines from frozen shoulder fibroblasts in
response to IL-17A stimulation, which would result in a conducive
inflammatory environment for the recruitment and activation of
T cells. Of particular note was the ability of IL-17A to initiate a
significant release of CCL20 from frozen shoulder fibroblasts. One
of the main functions of this chemokine is the recruitment of
CCR6+ IL-17A–producing T cells in disease (45, 57). We postulate
that there may be a positive chemotactic feedback loop which results
in the perpetual recruitment of IL-17A–producing cells due to
continuous IL-17A exposure and subsequent CCL20 release (Fig. 6).
IL-17A can signal through both NF-κB–dependent and inde-
pendent mechanisms; however, the current data indicate IL-17A
signaling in these cells was NF-κB dependent. The NF-κB signaling
pathway plays a central role in inflammation and cell survival (58).
By selectively inhibiting this pathway, we were able to successfully
impede the profibrotic and inflammatory IL-17A–induced changes
in frozen shoulder fibroblasts. We have previously demonstrated
the use of a small molecule inhibitor of NF-κB can be of thera-
peutic benefit to another connective tissue disease (49), and these
current data further support the potential of small molecule in-
hibitors as prospective therapeutic agents.
The downstream effects of NF-κB and IL-17A are ultimately
governed by the interaction of IL-17A with its cognate recep-
tor(s). In the case of frozen shoulder, IL-17RA appears to be the
principal signaling receptor. The lack of IL-17RA has been shown
to protect mice from repeated challenges that cause liver injury,
profibrotic cytokine expression, and fibrosis with collagen deposi-
tion (18). Although we have previously shown that frozen shoulder
fibroblasts produce more inflammatory proteins compared to non-
diseased cells (15), here we also demonstrate the magnitude of IL-
17A downstream effects are greater in diseased cells compared to
normal as a result of increased expression of IL-17RA in diseased
cells. Interestingly, this appears to be a feature of diseased fibro-
blasts from a number of pathologies (17, 23), indicating that either
mechanical or inflammatory trauma can render these cells more
susceptible to IL-17A, resulting in disease chronicity. Thus, the
targeting of this cytokine–receptor interaction is of therapeutic
potential in a number of pathologies. Furthermore, the role of IL-
17A is well documented in a number of inflammatory diseases such
as psoriatic arthritis, ankylosing spondylitis, and rheumatoid arthritis
(35, 36). Psoriatic arthritis and ankylosing spondylitis in particular
have been found to be clinically responsive to anti–IL-17A treat-
ment (28, 29). This has recently been extended to musculoskeletal
soft tissue tendon disease with the completion of a Phase II trial
(30). Furthermore, there is increasing evidence to suggest that IL-
17A may also have a central role in the pathogenesis of systemic
sclerosis (59, 60), a progressive fibrotic disorder. These studies, in
addition to current data, indicate that fibrosis and inflammation are
not two distinct means of disease development; rather, these pro-
cesses are intertwined in chronic diseases. Thus, the data from the
present study further support the potential benefit of exploring
anti–IL-17A as a nonsurgical intervention in a debilitating chronic
fibrotic disorder in which pharmaceutical treatments are limited.
We acknowledge that our experimental datasets lack in vivo
animal data. Although a number of animal models have been
used to study cytokine-driven fibrotic pathogenesis, there is no well-
described in vivo model available for frozen shoulder. Those that
have described in vivo models have tended to inject TGF-β (56)
into the joint or use joint immobilization (61) to directly explore the
fibrotic pathways more so than the inflammatory mechanisms of
disease, which may result in fibrosis. Additionally, in the current
study, we primarily measure gene expression of matrix proteins
rather than the physical proteins following IL-17A exposure.
However, this was principally to highlight changes in these matrix
protein genes that were due directly to IL-17A stimulation, and any
subsequent intervention in the IL-17A pathway would impede
changes in these genes. Furthermore, we have previously demon-
strated that diseased fibroblasts from frozen shoulder have an
“activated” phenotype which accompanies elevated baseline in-
flammation compared to control fibroblasts (15). This inflamma-
tory phenotype could influence some of the in vitro effects observed
in the current study; however, by directly inhibiting the signaling
and cytokine–receptor binding, we believe we have demonstrated
the clear and direct effect of IL-17A on diseased fibroblasts. Lastly,
we note that our control capsule samples were younger than the
frozen shoulder samples, and thus, some aspects may be due to
aging effects. However, obtaining nondiseased control tissue from
human subjects is extremely difficult, particularly from older pa-
tients who predominantly have some degree of deterioration of soft
tissue irrespective of diagnosis. We have consciously used capsule
tissue as a control rather than use healthy soft tissue obtained from
another anatomical site as a pseudocontrol.
In summary, the current study establishes a role for IL-
17A–driven pathogenesis in frozen shoulder. The shift from a
primarily macrophage-dominant to a T cell–rich immune reper-
toire signifies the importance of the immune cell landscape in
regulating disease chronicity in frozen shoulder. In addition,
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through dissection of the signaling pathways involved in the pro-
fibrotic and inflammatory processes, we suggest that targeting of
IL-17A signaling with readily available pharmaceutical agents may
provide novel nonsurgical early interventions for frozen shoulder.
Materials and Methods
Study Design. The purpose of the current study was to dissect the role of
inflammation, particularly the IL-17A pathway, in the manifestation of fro-
zen shoulder. Additionally, we aimed to identify if this pathway could be
suitably targeted for therapeutic intervention. We aimed to identify changes
in immune cell landscape influencing the diseased environment in frozen
shoulder, particularly IL-17A–secreting cells. Next, we investigated the fibrotic
and inflammatory effects of IL-17A, in vitro, and then sought to investigate
the mechanism by which diseased cells were more responsive to IL-17A stim-
ulation. Finally, we sought to identify if the pathways identified could be
targeted using readily available pharmacological agents that could inhibit the
pathways involved in frozen shoulder.
Study Approval. Human study procedures and protocols were approved by
the National Health Service West of Scotland Ethics Committee (Research
Ethics Committee 11/S0704/7). Full informed consent was obtained from all
patients. Sample size for tissue- and cell-based assays were determined based
on sample availability and technical needs.
Clinical Samples. Frozen shoulder tissue was collected from patients with
primary frozen shoulder undergoing surgical arthroscopic capsular release
(n = 10, 7 females, 3 males, mean age 52 ± 10.2 SEM). Control tissue was
obtained from patients undergoing arthroscopic stabilization surgery, un-
affected by any primary shoulder disease (n = 10, 3 females, 7 males, mean
age 31.3 ± 14.6 SEM). Tissue was characterized as macroscopically at the time
of surgery and microscopically by hematoxylin and eosin staining prior to
any control experiments (SI Appendix, Fig. S1).
Histology. Tissue was fixed in 4% paraformaldehyde and embedded in par-
affin using standard techniques. Sections (5 μm) were obtained and stained
with hematoxylin and eosin (Vector Laboratories).
Ex Vivo Stimulation. Tissue was digested in Liberase TM (Sigma-Aldrich) in
Roswell Park Memorial Institute (RPMI) media for a maximum of 2 h at 37 °C.
Digested tissue was then passed through a 100-μm cell strainer, pelleted by
centrifugation at 350 g for 5 min, and the supernatant was discarded. This
was repeated twice. Cells were either harvested for flow cytometry or un-
derwent the appropriate stimulation for 24 listed prior to harvesting for
intracellular flow cytometry. T cells were activated by stimulating the dis-
aggregated cell suspension for 24 h with Phorbol 12-myristate 13-acetate
(50 ng/mL) plus ionomycin (1 μg/mL) (all Sigma-Aldrich).
Fibroblast Isolation and Culture. Control and diseased fibroblasts were extracted
from stabilization and frozen shoulder capsule tissue, respectively. Tissue was
disaggregated as described above and cell suspension resuspended in supple-
mented culture medium (RPMI with 10% fetal bovine serum 1% penicillin/
streptomycin and 1% L-glutamine [all Invitrogen]) at 37 °C, 5% CO2, and 95%
humidity. Cultures were maintained at 37 °C in a humidified atmosphere of 5%
CO2. Cells were subcultured and trypsinized at sub confluency and used at
passage 2 to 4. Fibroblasts used for in vitro experiments were analyzed via qPCR
to assess any endothelial or immune cell contamination (SI Appendix, Table 1).
In Vitro Fibroblast Stimulation. Cells were plated in 24-well culture plates at a
density of 2.5 × 104 cells per well with 0.5 mL supplemented culture medium
and allowed to adhere 48 h prior to stimulation. Cells were stimulated with
recombinant human IL-17A (1 to 100 ng/mL) (BioLegend) diluted in sup-
plemented culture medium for 24 h unless stated below. After the stimu-
lation period, supernatants were collected and cells harvested for the
appropriate assay.
For cell proliferation and viability assays and cytosol/mitochondrial frac-
tionation, cells were serum starved overnight prior to stimulation; the
stimulation period was 72 h.
Fig. 6. Targeting IL-17A in frozen shoulder. Schematic diagram illustrating possible IL-17A–driven pathogenesis in frozen shoulder. The presence of IL-
17A–secreting T cells results in the fibrosis, inflammation, and further recruitment of pathogenic T cells, resulting in disease chronicity, which can be at-
tenuated by use of an anti–IL-17A monoclonal antibody.
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In the inhibitor studies, cells were seeded as above for 48 h. The cells were
then pretreated with the appropriate inhibitor or control for 30 min prior to
IL-17A stimulation for 24 h. The concentrations and relevant control are as
follows: 50 mM IKKβ inhibitor VIII (Merck) and dimethyl sulfoxide control,
10nM anti–IL-17A (Secukinumab, Novartis), and IgGκ (BioLegend) compared
to vehicle-treated controls. Following the stimulation period, supernatants
were collected and cells harvested for the appropriate assay. The superna-
tant was sampled to determine inflammatory cytokine concentration, and
RNA was isolated from cell lysates.
Viability Assay. Cell viability was assessed using the TOX1kit (MTT 3-
(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide based) as per
the manufacturers protocol (Sigma-Aldrich).
BrdU Assay. Cell proliferation was assessed using the BrdU Cell Proliferation
Kits per the manufacturers protocol (Sigma-Aldrich). BrDU reagent was
added in the final 24 h of the experiment.
Mitochondria/Cytosol Fractionation. Enriched mitochondrial and cytosolic
fractions were obtained from fibroblasts using a Mitochondria/Cytosol
Fractionation Kit (Abcam) as per the manufacturers protocol.
Enzyme-Linked Immunosorbent Assay. Chemokine, cytokine, cytochrome C,
and MMP3 concentration was determined using enzyme-linked immuno-
sorbent assay kits as per the manufacturers protocol; CCL20 (BioLegend),
cytochrome C, IL-6, IL-8 (all Invitrogen), and MMP3 (R&D Systems).
Western Blot. Cells were seeded in 6-well plates as described above for 48 h
but at a density of 1 × 106 in 3 mL culture medium. Following this period, the
culture medium was replaced with 2 mL fresh culture medium for 2 h. Cells
were lysed with radioimmunoprecipitation assay lysis buffer supplemented
with Halts protease and phosphatase inhibitors (Thermo Fisher Scientific).
Total protein was quantified with the Pierce BCA Protein Assay Kit (Thermo
Fisher Scientific). Equal amounts of total cell lysate (30 mg per well) were
subjected to sodium dodecyl sulfate electrophoresis on 4 to 12% Bis-Tris gels
(Thermo Fisher Scientific). Gels were run at a constant voltage of 100 mV
(PowerPac 3000, Bio-Rad) and transferred onto a nitrocellulose membrane
with the iBlot2 Transfer System (Thermo Fisher Scientific) as per manufac-
turer’s instructions. Immunoblotting was completed for GAPDH, IL-17RA,
TRAF6 (all Cell Signaling Technology), and IL-17RC (Abcam). A Li-Cor Azure
C500 imager was used to visualize immunoblots, and ImageJ software (NIH)
was used for quantification.
Flow Cytometry. Single-cell suspensions were labeled with fluorophore-
conjugated anti-mouse antibodies (Table 1) and Zombie viability dye at rec-
ommended dilutions following themanufacturers’ recommendations (BioLegend).
Data were acquired on a BD LSR II using FACS DIVA software with automated
compensation (BD Biosciences). Compensation data were acquired using
single stained BD Comp beads as per manufacturer’s instructions (BD Biosciences).
All data were analyzed using FlowJo software (BD Biosciences).
Single-Cell RNA Sequencing. Single-cell suspensions of cells were derived from
freshly digested tendon biopsies following surgical excision as described
above. Live cells were sorted using a FACS ARIA III. Isolated cells were lysed,
and then RNA was reverse transcribed and converted to complementary
DNA (cDNA) libraries for RNA sequencing analysis using a Chromium Con-
troller and Chromium Single-Cell 3′ v2 Reagent kit (10x Genomics) following
the manufacturer’s protocol. Pooled libraries were used for sequencing on a
HiSeq 4000 (Illumina) to a depth of ∼30,000 reads per cell. The alignment of
reads to the genome and generation of gene counts per cell were per-
formed by Cell Ranger software (10x Genomics). Quality control was per-
formed on each sample, and poor-quality cells were removed on the basis of
number of genes expressed (>200), of unique molecular identifiers, and
percentage of mitochondrial reads mapped (>5%). Using the Seurat Pack-
age (Sajita Lab), we normalized and scaled the data. Following this, principal
components analysis and high-quality cells were clustered using a graph-
based routine implemented in the Seurat R package (Satija Lab).
Gene Expression. Cells were harvested in PureLink lysis buffer containing 1%
2-mercaptoethanol, and RNAwas extracted using mini columns according to the
PureLink protocol (Thermo Fisher Scientific). RNA concentration and purity were
determined using a spectrophotometer (Nanodrop 2000, Thermo Scientific), and
100 ng RNA was converted to cDNA using the High-Capacity cDNA Reverse
Transcription Kit (Thermo Fisher Scientific) according to manufacturer’s instruc-
tions. cDNA was diluted 1 in 5 using RNase free water. qPCR was performed
using PowerUp Sybr Green Mastermix (Thermo Fisher Scientific). Each sample
was run in duplicate and normalized to endogenous control (GAPDH) following
confirmation that there was no more than 0.25 cycles difference in the control
gene between each treated condition. Data represents relative mRNA expres-
sion to housekeeping gene (2−ΔCT) or fold change from untreated cells (2−ΔΔCT).
Primers (Integrated DNA Technologies) were as follows:
GAPDH (f) 5′-TCGACAGTCAGCCGCATCTTCTTT-3′, (r) 5′-ACCAAATCCGTT-
GACTCCGA CCTT-3′, PDPN (f) 5′-CTTGACAACTCTGGTGGA-3′, (r) 5′-GGG-
CTTGGACTTGTTCTTG-3′, CD45 (f) 5′-AAAGCCCAACACCTTCCC-3′, (r) 5′-
AGTAGCTATTGTTGTGGTTGAAATG-3′, CD31 (f) 5′-ATTCCTGAAGTCCGG-
ATCTATG-3′, (r) 5′-GGACTGGGCACTCCTTC-3′, COL1A1 (f) 5′-CAA TGC
TGC CCT TTC TGC TCC-3′, (r) 5′-CAC TTG GGT GTT TGA GCA TTG-3′, COL3A1
(f) 5′-TAT CGA ACA CGC AAG GCT GTG-3′, (r) 5′-GGC CAA CGT CCA CAC
CAA ATT-3′, TNC (f) 5′-CTTTGGCTGGGTTGCTTGAC-3′ (r) 5′-GTGCCAGGA-
GACCGTACCAC-3′, FN1 (f) 5′-TTG TAC TTG CCT GGG AGA AG-3′, (r) 5′-CTC-
CAGGTGTCTCCAATTCTAT-3′, MMP1 (f) 5′-TGC GCA CAA ATC CCT TCT-3′, (r)
5′-AGC CCA GTA CTT ATT CCC TTT G-3′, MMP3 (f) 5′-ACC CGA CCT TAC ATA
CAG GAT T-3′, (r) 5′-GTC ACC TCT TCC CAG ACT TTC-3′, α-SMA (f) 5′-CCT CCC
TTG AGA AGA GTT ACG A-3′, (r) 5′-GAC TCC ATC CCG ATG AAG GAT-3′,
BCL2 (f) 5′-AGG CTG GGA TGC CTT TGT -3′, (r) 5′-GAC TTC ACT TGT GGC CCA
GAT A-3′, BAX (f) 5′-GGA GCT GCA GAG GAT GAT TG -3′, (r) 5′-AGT TGAAGT
TGC CGT CAG AA-3′, CCND1 (f) 5′-TGT GCC ACA GAT GTG AAG TT-3′, (r) 5′-
GTA GTA GGA CAG GAA GTT GTT GG-3′, IL-6 (f) 5′-CAC TCA CCT CTT CAG
AAC GAA T-3′, (r) 5′-GCT GCT TTC ACA CAT GTT ACT C-3′, IL-8 (f) 5′-GTG CAT
AAA GAC ATA CTC CAA ACC-3′, (r) 5′-GCT TTA CAA TAA TTT CTG TGT TGG
C-3′, IL-17A (f) 5′-TCT GCT ATT CTG GAT ACT GCT TTC -3′, (r) 5′-TCT GTG GAG
TAC TTT GTT CAC C -3′, IL-17B (f) 5′-TGT CAC GGA TGA AAC CGT ATG-3′, (r)
5′-TTC TCT GGG CCA GCT CT-3′, IL-17C (f) 5′-CCA CCA TGA CGC TCC TC-3′, (r)
5′-TCA GCC GAG TAG CAG TGT-3′, IL-17D (f) 5′-TGG GCC TAC AGA ATC TCC
TA-3′, (r) 5′-GAC GGT GGG CAT GTA GAC-3′, IL-17E (f) 5′-CCC TGG AGA TAT
GAG GCT T-3′, (r) 5′-TGC ACT GAC CTG GTA CAT-3′, IL-17RA (f) 5′-GAT TCA
CCC TCG AAA CCT GA-3′, (r) 5′-ATG CTG GCG TCT GTC TG-3′, IL-17RC (f) 5′-
CGT GCA TCT GGT TCT GAA TG-3′, (r) 5′-GCG GTC CAG TCA GGT TT-3′, CCL2
(f) 5′-CTC AGC CAG ATG CAA TCA ATG-3′, (r) 5′-TGC TGC TGG TGA TTC TTC
TAT-3′, CCL5 (f) 5′-GCT GCT TTG CCT ACA TTG C-3′, (r) 5′-CTT TCG GGT GAC
AAA GAC GA-3′, CCL20 (f) 5′-GTC TTG GAT ACA CAG ACC GTA TT-3′, (r) 5′-
GTG TGA AAG ATG ATA GCA TTG ATG T-3′.
Statistical Analysis. All data are shown as means ± SD. All statistical analyses
were performed following a Shapiro–Wilk normality test on the data using
GraphPad Prism 7 software. Individual tests for each dataset are described in
the relevant figure legend. A P value < 0.05 was considered significant.
Data Availability. Raw UMI counts and normalized expression values for
single-cell RNA-Seq are publicly available at https://owncloud.gla.ac.uk/cloud/
s/e4pZdcSzN1EClhE. Individual sequencing read data will be available on
request under the condition of approval of the ethics committee of Glasgow
University and material transfer agreement. All other study data are in-
cluded in the article and/or SI Appendix.
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